세계의 발작성 야간혈색소뇨증 치료제 시장 : 치료별, 약제별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,520,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,467,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,858,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 하이라이트

발작성 야간혈색소뇨증 치료제(Paroxysmal Nocturnal Hemoglobinuria Drug) 시장 규모는 2022년 34억 7,020만 달러였으며, 2023년부터 2030년까지 CAGR 13.8%로 추이하며 성장할 것으로 예상됩니다.

발작성 야간혈색소뇨증 치료제 시장 - 시장 역학 :

• 규제 당국의 승인과 연구 개발의 확대가 시장 성장을 견인합니다.
• 세계의 발작성 야간혈색소뇨증 치료제 시장 동향은 유럽 의약품청(EMA), 미국 식품의약국(FDA) 및 기타 국제 규제 기관과 같은 기관의 규제 승인에 크게 의존합니다. eculizumab과 ravulizumab의 시장 입지와 환자 접근성은 승인을 통해 탄탄한 기반을 마련한 덕분입니다. 또한, 새로운 치료 대안을 발견하고 기존 치료법을 개선하려는 시도는 PNH 분야에서 지속적인 연구 개발의 주요 목표입니다. 여기에는 병용 의약품 연구, 혁신적인 표적 치료제 개발, 대체 투여 기술 등이 포함됩니다. 이러한 개발과 혁신은 PNH 의약품 산업이 확장하고 발전하는 데 도움이 됩니다.

발작성 야간혈색소뇨증 치료제 시장-세분화 분석 :

• 발작성 야간혈색소뇨증 치료제 시장은 치료, 약제, 투여 경로, 최종 사용자 및 지역에 따라 세분화됩니다.
• 치료법에 따라 시장은 투약, 보충제, 수혈, 골수 이식으로 이분됩니다. 예측 기간 동안 수혈 분야가 시장을 독점할 것으로 예상됩니다. 수혈은 빈혈의 증상을 완화하는 데 도움이되는 치료법 중 하나입니다. PNH는 혈전증을 포함한 큰 부작용을 일으키고 방치하면 죽음에 이르기도 합니다. PNH 환자는 빈혈 증상을 치료하기 위해 수혈을 자주 필요로 하는데, 이는 수혈 중에 환자가 기증자로부터 혈액 또는 혈액 제형을 받기 때문입니다. 따라서 시장 성장의 원동력이 되고 있습니다.

발작성 야간혈색소뇨증 치료제 시장-지리적 통찰

지역적으로, 이 시장은 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카 등 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 제공하는 국가에 의해 더욱 세분화됩니다. 북미는 예측 기간 동안 시장을 지배 할 것으로 예상됩니다. PNH에 대한 표적 치료제를 개발하고 홍보하는 주요 제약 회사가 이 지역의 PNH 약물 시장을 지배하고 있습니다. 현재 AstraZeneca의 사업부인 Alexion Pharmaceuticals Inc와 eculizumab(Soliris라는 이름으로 판매)과 같은 회사는 시장 환경에 상당한 영향을 미쳤습니다. 또한 PNH 치료제의 승인과 가용성은 북미, 특히 미국의 규제 환경에 크게 영향을 받습니다. eculizumab과 ravulizumab(Ultomiris라는 브랜드로 판매)과 같은 PNH 치료를 위한 표적 치료제는 미국 식품의약국(FDA)의 승인을 받았으며, 이는 이 지역에서 광범위하게 사용되는 데 기여했습니다.

발작성 야간혈색소뇨증 치료제 시장-경쟁 구도 :

세계 심해 탄화수소 탐사 시장의 선도 기업들은 제품 라인업을 다양화하기 위해 연구 개발 활동을 강화하고 있습니다. 또한 이러한 시장 진출기업들은 성장을 가속하는 전략적 제휴와 파트너십을 활용하고 있습니다. 시장에서 사업을 전개하는 주요 기업은 Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, BioCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd, LGM Pharma, Lannett, Achillion Pharmaceuticals Inc, Amgen Inc 등이 있습니다.

목차

제1장 발작성 야간혈색소뇨증 치료제 시장 개요

• 조사 범위
• 시장 추정 연도

제2장 주요 요약

• 시장 분석
• 경쟁 인사이트

제3장 발작성 야간혈색소뇨증 치료제-주요 시장 동향

• 시장 성장 촉진 요인
• 시장 성장 억제 요인
• 시장 기회
• 향후 시장 동향

제4장 발작성 야간혈색소뇨증 치료제-산업 연구 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 맵핑
• 규제 프레임워크 분석

제5장 발작성 야간혈색소뇨증 치료제 시장 : COVID-19 영향 분석

• COVID-19 이전 영향 분석
• COVID-19 이후 영향 분석

제6장 발작성 야간혈색소뇨증 치료제 시장 상황

• 발작성 야간혈색소뇨증 치료제 시장 점유율 분석(2022년)
• 주요 제조사별 분석 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 발작성 야간혈색소뇨증 치료제 시장-치료별

• 개요
  • 치료별 부문 점유율 분석
  • 약
  • 보충제
  • 수혈
  • 골수 이식

제8장 발작성 야간혈색소뇨증 치료제 시장-약제별

• 개요
  • 제약별 부문 점유율 분석
  • eculizumab
  • ravulizumab
  • 기타

제9장 발작성 야간혈색소뇨증 치료제 시장-투여 경로별

• 개요
  • 투여 경로별 부문 점유율 분석
  • 경구
  • 비경구

제10장 발작성 야간혈색소뇨증 치료제 시장-최종 사용자별

• 개요
  • 최종 사용자별 부문 점유율 분석
  • 병원
  • 홈케어
  • 전문 클리닉
  • 기타

제11장 발작성 야간혈색소뇨증 치료제 시장-지역별

• 소개
• 북미
  • 개요
  • 북미의 주요 제조사
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조사
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아 태평양(APAC)
  • 개요
  • 아시아 태평양의 주요 제조사
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 남미
  • 개요
  • 남미의 주요 제조사
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조사
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제12장 주요 벤더 분석-발작성 야간혈색소뇨증 제약 산업

• 경쟁 대시보드
• 기업 개요
  • Ra Pharmaceuticals Inc
  • CinnaGen Co
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals
  • Abbott
  • NorthStar Rx LLC
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • BIOCAD
  • Samsung Bioepis
  • Amyndas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • LGM Pharma.
  • Lannett
  • Achillion Pharmaceuticals Inc
  • Amgen Inc

제13장 애널리스트의 전방위 전망

LYJ

영문 목차

영문목차

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.

Red blood cells are destroyed (hemolyzed) and aberrant red blood cells are present in the circulation in paroxysmal nocturnal hemoglobinuria (PNH), an uncommon and possibly fatal blood condition. It results from excessive activation of the complement system, a component of the immune system in charge of removing foreign substances in the body, which is brought on by a genetic mutation that affects the proteins on the surface of red blood cells.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

• Growing regulatory approvals and R&D drives market growth

• The developments of the worldwide paroxysmal nocturnal hemoglobinuria medicine market heavily depend on regulatory approvals from organizations like the European Medicines Agency (EMA), the U.S. Food and medicine Administration (FDA), and other international regulatory agencies. Eculizumab and ravulizumab's market presence and patient accessibility have benefited from their approval, which has laid a solid basis. Additionally, attempts to discover novel therapy alternatives and enhance existing therapies are the main goals of continuing research and development in the field of PNH. This includes investigating combination medicines, developing innovative targeted therapeutics, and alternate administration techniques. These developments and breakthroughs help the PNH drugs industry expand and develop.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

• As per the analysis shared by our research analyst, the global Paroxysmal Nocturnal Hemoglobinuria Drug market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)

• The Paroxysmal Nocturnal Hemoglobinuria Drug industry is projected to grow at a significant rate owing to the growing regulatory approvals

• Based on treatment, the blood transfusion segment is expected to dominate the market over the forecast period

• Based on region, North America is expected to dominate the market over the forecast period

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

• The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is segmented based on treatment, drugs, route of administration, end user, and Region.

• Based on treatment, the market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The blood transfusion segment is expected to dominate the market over the forecast period. Blood transfusion is one of the therapies that might help to lessen the symptoms of anemia. PNH causes major adverse effects including thrombosis and can be deadly if left untreated. PNH patients frequently require blood transfusions to treat their anemic symptoms because, during a transfusion, the patients receive blood or blood products from a donor. Thus, driving the market growth.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. Major pharmaceutical firms that create and promote targeted therapy for PNH dominate the region's PNH medication market. Companies like Alexion Pharmaceuticals, which is now a division of AstraZeneca, and the medicine eculizumab (marketed under the name Soliris), have had a substantial impact on the market environment. Additionally, the approval and availability of PNH medications are greatly influenced by the regulatory climate in North America, notably the United States. Targeted treatments for the treatment of PNH, such as eculizumab and ravulizumab (marketed under the brand Ultomiris), have been approved by the U.S. Food and Drug Administration (FDA), which has contributed to their extensive usage in the area.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Leading companies in the worldwide Deepwater Hydrocarbon Exploration market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, Achillion Pharmaceuticals Inc and Amgen Inc.

Recent Developments:

In September 2023, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for crovalimab, an experimental, brand-new anti-C5 recycling monoclonal antibody, to treat paroxysmal nocturnal hemoglobinuria (PNH), according to Chugai Pharmaceutical Co., Ltd. The acceptance was based on the key phase III COMMODORE 2 study's findings, which showed that crovalimab effectively controlled illness and was well tolerated in PNH patients.1 Crovalimab's constant benefit-risk profile as seen in the phase III COMMODORE 1 study's findings provided additional evidence for the application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

• Ra Pharmaceuticals Inc
• CinnaGen Co
• Akari Therapeutics Plc
• Alexion Pharmaceuticals Inc
• Apellis Pharmaceuticals
• Abbott
• NorthStar Rx LLC
• Alnylam Pharmaceuticals Inc
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Regeneron Pharmaceuticals Inc
• BIOCAD
• Samsung Bioepis
• Amyndas Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• LGM Pharma.
• Lannett
• Achillion Pharmaceuticals Inc
• Amgen Inc

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

• Medication
• Supplements
• Blood Transfusion
• Bone Marrow Transplant

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

• Eculizumab
• Ravulizumab
• Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

• Oral
• Parenteral

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

• Hospitals
• Homecare
• Specialty Clinics
• Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

• North America
• The U.S.
• Canada

• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe

• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC

• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM

• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
  • 2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
  • 2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
  • 2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
  • 2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
  • 2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
• 2.2. Competitive Insights

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

• 3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
• 3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

• 6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
  • 7.1.2. Medication
  • 7.1.3. Supplements
  • 7.1.4. Blood Transfusion
  • 7.1.5. Bone Marrow Transplant

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
  • 8.1.2. Eculizumab
  • 8.1.3. Ravulizumab
  • 8.1.4. Others

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
  • 9.1.2. Oral
  • 9.1.3. Parenteral

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
  • 10.1.2. Hospitals
  • 10.1.3. Homecare
  • 10.1.4. Specialty Clinics
  • 10.1.5. Others

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.9. Italy
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.10. United Kingdom
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.11. France
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.12. Russia
    • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.13. Netherlands
    • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.15. Poland
    • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3.16. Rest of Europe
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
  • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.8. India
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.9. China
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.13. Thailand
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.14. Indonesia
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
• 11.5. Latin America
  • 11.5.1. Overview
  • 11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
  • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
• 11.6. Middle East and Africa
  • 11.6.1. Overview
  • 11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
  • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
  • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
  • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

• 12.1. Competitive Dashboard
• 12.2. Company Profiles
  • 12.2.1. Ra Pharmaceuticals Inc
  • 12.2.2. CinnaGen Co
  • 12.2.3. Akari Therapeutics Plc
  • 12.2.4. Alexion Pharmaceuticals Inc
  • 12.2.5. Apellis Pharmaceuticals
  • 12.2.6. Abbott
  • 12.2.7. NorthStar Rx LLC
  • 12.2.8. Alnylam Pharmaceuticals Inc
  • 12.2.9. F. Hoffmann-La Roche Ltd
  • 12.2.10. Novartis AG
  • 12.2.11. Regeneron Pharmaceuticals Inc
  • 12.2.12. BIOCAD
  • 12.2.13. Samsung Bioepis
  • 12.2.14. Amyndas Pharmaceuticals
  • 12.2.15. Teva Pharmaceutical Industries Ltd.
  • 12.2.16. LGM Pharma.
  • 12.2.17. Lannett
  • 12.2.18. Achillion Pharmaceuticals Inc
  • 12.2.19. Amgen Inc

13. 360 Degree Analyst View

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us

관련자료